Originally published as JCO Early Release 10.1200/JCO.2002.09.030 on July 9 2002

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Raymond, E. Articles by Schellens, J.H.M. Search for Related Content PubMed PubMed Citation Articles by Raymond, E. Articles by Schellens, J.H.M. Social Bookmarking                            What's this?

Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer

From the Institut Gustave-Roussy, Villejuif, France; Netherlands Cancer Institute and NDDO Oncology, Amsterdam, the Netherlands; and Eisai Limited, London, United Kingdom.

Address reprint requests to Eric Raymond, MD, PhD, Department of Medicine, Institut Gustave Roussy, 39 Rue Camille Desmoulins 94805 Villejuif, France; email: raymond{at}igr.fr

PURPOSE: The objectives were to determine the maximum-tolerated dose, the recommended dose, the dose-limiting toxicity, the pharmacokinetics, and the activity of E7070, a novel cell-cycle inhibitor.

PATIENTS AND METHODS: E7070 was given as a 1-hour intravenous infusion every 3 weeks in two groups of patients with advanced solid tumors who met prespecified eligibility criteria (group A) or who met the same eligibility criteria but in addition were less heavily pretreated and had more favorable liver functions (group B).

RESULTS: Forty patients (31 patients in group A and nine patients in group B) were entered. Dose escalation proceeded through eight levels (range, 50 to 1,000 mg/m²). In group A, neutropenia and thrombocytopenia were dose-limiting toxicities occurring during the first cycle in two of seven patients treated at the doses of 700 mg/m² and two of four patients treated at 800 mg/m². Identical dose-limiting toxicities were observed in zero of six and two of three patients from group B at doses of 800 and 1,000 mg/m², respectively. Other toxicities included acne-like skin eruption, mucositis, conjunctivitis, nausea, fatigue, and alopecia. At doses greater than 400 mg/m², the area under the concentration-time curve increased disproportionately to the administered dose. Tumor stabilization lasting 6 months was observed in six assessable patients.

CONCLUSION: The recommended doses of E7070 in this schedule were 700 mg/m² (group A) and 800 mg/m² in patients who were less heavily pretreated (group B) with a moderate tumor burden. Prolonged disease stabilization observed in this study might warrant further investigation of E7070 in selected tumor types.

This article was published ahead of print at www.jco.org.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. S. Zandvliet, A. D.R. Huitema, W. Copalu, Y. Yamada, T. Tamura, J. H. Beijnen, and J. H.M. Schellens CYP2C9 and CYP2C19 Polymorphic Forms Are Related to Increased Indisulam Exposure and Higher Risk of Severe Hematologic Toxicity Clin. Cancer Res., May 15, 2007; 13(10): 2970 - 2976. [Abstract] [Full Text] [PDF]

				D. C. Talbot, J. von Pawel, E. Cattell, S. M. Yule, C. Johnston, A. S. Zandvliet, A. D.R. Huitema, C. J. Norbury, P. Ellis, L. Bosquee, et al. A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., March 15, 2007; 13(6): 1816 - 1822. [Abstract] [Full Text] [PDF]

				A. S. Zandvliet, W. Copalu, J. H. M. Schellens, J. H. Beijnen, and A. D. R. Huitema SATURABLE BINDING OF INDISULAM TO PLASMA PROTEINS AND DISTRIBUTION TO HUMAN ERYTHROCYTES Drug Metab. Dispos., June 1, 2006; 34(6): 1041 - 1046. [Abstract] [Full Text] [PDF]

				J. F. Smyth, S. Aamdal, A. Awada, C. Dittrich, F. Caponigro, P. Schoffski, M. Gore, T. Lesimple, N. Djurasinovic, B. Baron, et al. Phase II study of E7070 in patients with metastatic melanoma Ann. Onc., January 1, 2005; 16(1): 158 - 161. [Abstract] [Full Text] [PDF]

				C. Dittrich, H. Dumez, H. Calvert, A. Hanauske, M. Faber, J. Wanders, M. Yule, M. Ravic, and P. Fumoleau Phase I and Pharmacokinetic Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent, Administered on a Weekly Schedule to Patients with Solid Tumors Clin. Cancer Res., November 1, 2003; 9(14): 5195 - 5204. [Abstract] [Full Text] [PDF]